within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AB12_Bemiparin;

model Bemiparin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.444444444444445e-08,
    adminDuration = 600,
    adminMass = 3.5 / 1000000,
    adminCount = 1,
    Vd = 0.0058,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bemiparin</td></tr><tr><td>ATC code:</td><td>B01AB12</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>3.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.16</td><td>liter/hour</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bemiparin is a low molecular weight heparin (LMWH) used as an anticoagulant for the prevention and treatment of deep vein thrombosis (DVT) and thromboembolic disorders. It has antithrombotic and anti-Xa activity, with reduced anti-IIa activity compared to unfractionated heparin. It is approved for prophylaxis and treatment of venous thromboembolism, especially in surgical patients, and is used in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters determined after subcutaneous administration of single prophylactic dose in healthy adult volunteers.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AB12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bemiparin;
